How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,480 results for

Potassium Replacement

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. Full Text available with Trip Pro

Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. No consensus exists for optimization of mineralocorticoid therapy in patients with primary adrenal insufficiency.To explore the relationship between mineralocorticoid (MC) replacement dose, plasma renin concentration (PRC), and clinically important variables to determine which are most helpful in guiding MC dose titration in primary adrenal insufficiency.Observational (...) , electrolytes, blood pressure (BP), and anthropometric parameters were used to predict their utility in optimizing MC replacement dose.PRC was low, normal, or high in 19%, 36%, and 44% of patients, respectively, with wide variability in MC dose and PRC. Univariate analysis demonstrated a direct positive relationship between MC dose and PRC in adults and children. There was no relationship between MC dose and BP in adults, while BP increased with increasing MC dose in children. Using multiple regression

2020 Journal of Clinical Endocrinology and Metabolism

22. Mediators of the Impact of Hourly Net Ultrafiltration Rate on Mortality in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. (Abstract)

, hemodynamic instability, or low potassium or phosphate blood levels using mediation analysis and the primary outcome was hospital mortality.Retrospective, observational study.Mixed medical and surgical ICUs at Austin hospital, Melbourne, Australia.Critically ill patients treated with continuous renal replacement therapy within 14 days of ICU admission who survived greater than 48 hours.None.We studied 347 patients (median [interquartile range] age: 64 yr [53-71 yr] and Acute Physiology and Chronic Health (...) Mediators of the Impact of Hourly Net Ultrafiltration Rate on Mortality in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. During continuous renal replacement therapy, a high net ultrafiltration rate has been associated with increased mortality. However, it is unknown what might mediate its putative effect on mortality. In this study, we investigated whether the relationship between early (first 48 hr) net ultrafiltration and mortality is mediated by fluid balance

2020 Critical Care Medicine

23. Clinical effect and safety of continuous renal replacement therapy in the treatment of neonatal sepsis-related acute kidney injury. Full Text available with Trip Pro

Clinical effect and safety of continuous renal replacement therapy in the treatment of neonatal sepsis-related acute kidney injury. Sepsis is the leading cause of acute kidney injury (AKI) in the neonatal intensive care unit (NICU). The aim of the study is to explore the efficacy and security of continuous renal replacement therapy (CRRT) in the treatment of neonatal sepsis-related AKI.Totally12 sepsis-related AKI neonates treated with CRRT were hospitalized in the NICU of Shanghai Children's (...) , the blood pH value increased to the normal range (7.35 ~ 7.45). After 12 h CRRT treatment, the oxygenation index of 12sepsis-related AKI neonates could reach 200 mmHg. After 24 h CRRT treatment, it could rise to more than 300 mmHg. Serum potassium, serum urea nitrogen and serum creatinine levels decreased significantly 12 h after CRRT initiation, and reached the normal range 24 h after CRRT initiation. The urine volume significantly increased 24 h after CRRT initiation. (3) Venous catheterization

2020 BMC Nephrology

24. Planning, Initiating and Withdrawal of Renal Replacement Therapy

Planning, Initiating and Withdrawal of Renal Replacement Therapy - 1 - CLINICAL PRACTICE GUIDELINE Planning, Initiating and Withdrawal of Renal Replacement Therapy UK Renal Association 6 th Edition Final Version (based on literature up to Feb 2013) Graham Warwick, Consultant Nephrologist Andrew Mooney, Consultant Nephrologist Lynne Russon, Consultant in Palliative Medicine, Rebecca Hardy, SpR in Nephrology Posted at www.renal.org/guidelines Please check for updates Please send feedback (...) for the next edition to Graham Warwick at graham.warwick@uhl-tr.nhs.uk or Andrew Mooney at andrew.mooney@leedsth.nhs.uk - 2 - Contents Introduction Summary of Clinical Practice Guidelines for Planning, Initiating and Withdrawal of Renal Replacement Therapy 1. Timely nephrology referral (Guidelines 1.1-1.2) 2. Nephrology follow-up (Guidelines 2.1-2.3) 3. Preparing for renal replacement therapy (Guidelines 3.1-3.7) 4. Educating patients and carers for renal replacement therapy (Guidelines 4.1-4.3) 5

2014 Renal Association

25. Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. (Abstract)

Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. To control hyperthyroidism due to Graves' disease, antithyroid drugs should be administered. Several studies have shown that exposure to methimazole (MMI) during the first trimester of pregnancy increases the incidence of specific congenital anomalies that are collectively (...) referred to as MMI embryopathy. Congenital anomalies associated with exposure to propylthiouracil (PTU) have also recently been reported.This study investigated whether substituting potassium iodide (KI) for MMI in the first trimester would result in a lower incidence of major congenital anomalies than continuing treatment with MMI alone. The cases of 283 women with Graves' disease (GD) were reviewed whose treatment was switched from MMI to KI in the first trimester (iodine group), as well as the cases

2015 Thyroid

26. Is Potassium Supplementation Beneficial in Hospitalized Patients?

. 2015 Jan;128(1):60-7. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000 Sep 11;160(16):2429-36. Review. Conway R, Creagh D, Byrne DG, O’Riordan D, Silke B. Serum potassium levels as an outcome determinant in acute medical admissions. Clin Med (Lond). 2015 Jun;15(3):239-43. Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among (...) Is Potassium Supplementation Beneficial in Hospitalized Patients? Is Potassium Supplementation Beneficial in Hospitalized Patients? – Clinical Correlations Search Is Potassium Supplementation Beneficial in Hospitalized Patients? October 25, 2017 6 min read By Sara Stream, MD Peer Reviewed As resident physicians, we are taught to supplement serum potassium to a goal level of 4.0 mEq/L in all hospitalized patients. While the dangers of severe potassium abnormalities are well established

2017 Clinical Correlations

27. Effects of salt substitute on home blood pressure differs according to age and degree of blood pressure in hypertensive patients and their families. (Abstract)

of this current study was to assess the effects of a low-sodium and high-potassium salt substitute on HBP among hypertensive patients and their family members.A total of 220 households (including 220 hypertensive patients and 380 their families) were randomly assigned to the regular salt or salt substitute groups. HBP was measured at the beginning, 3rd, 6th, and 12th months. Among the patients (n = 220), only home systolic blood pressure (HSBP) was significantly reduced, by an adjusted baseline BP of 4.2 mm (...) Effects of salt substitute on home blood pressure differs according to age and degree of blood pressure in hypertensive patients and their families. It is known that home blood pressure (HBP) is a more reliable assessment of hypertension treatments than clinical blood pressure (BP). Despite this, HBP response to a salt substitute has only been evaluated by one study which, did not look at the salt substitute's effect on family members and did not analyze by age, gender, or BP degree. The aim

2018 Clinical and experimental hypertension (New York, N.Y. : 1993) Controlled trial quality: uncertain

28. Targeting matrix metalloproteinases with novel diazepine substituted cinnamic acid derivatives: design, synthesis, in vitro and in silico studies Full Text available with Trip Pro

inhibitors, should be an important goal in lung cancer therapy. In the present study, an effort has been made to develop new anti-metastatic and anti-invasive agents, wherein a series of novel diazepine substituted cinnamic acid derivatives were designed, synthesized and assayed for their inhibitory activities on MMP-2 and MMP-9. These derivatives were prepared via microwave assisted reaction of tert-butyl (3-cinnamamidopropyl)carbamate derivatives mixed with 2,3-dibromopropanoic acid and potassium (...) Targeting matrix metalloproteinases with novel diazepine substituted cinnamic acid derivatives: design, synthesis, in vitro and in silico studies Lung cancer is the notable cause of cancer associated deaths worldwide. Recent studies revealed that the expression of matrix metalloproteinases (MMPs) is extremely high in lung tumors compared with non-malignant lung tissue. MMPs (-2 and -9) play an important part in tumor development and angiogenesis, which suggests that creating potent MMP-2 and -9

2018 Chemistry Central journal

29. Association between salt substitutes/enhancers and changes in sodium levels in fast-food restaurants: a cross-sectional analysis Full Text available with Trip Pro

chain (n = 12) for which ingredient data were available. The most common substitutes/enhancers were yeast extracts (in 30% of foods), calcium chloride (28%), monosodium glutamate (14%) and potassium chloride (12%). Sodium levels in foods that contained substitutes/enhancers decreased significantly more (190 ± 42 mg/serving) over the study period than those in foods that did not contain a substitute/enhancer (40 ± 17 mg/serving, p < 0.001).Salt substitutes and enhancers are prevalent in restaurant (...) Association between salt substitutes/enhancers and changes in sodium levels in fast-food restaurants: a cross-sectional analysis Restaurant foods have high sodium levels, and efforts have been made to promote reductions. The objective of this study was to understand if salt substitutes and enhancers are associated with changes in sodium levels in fast-food restaurants.A longitudinal database (MENU-FLIP) containing nutrition information for Canadian chain restaurants with 20 or more locations

2018 CMAJ open

30. Neuropsiquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

Frame: 24 weeks ] Identify patterns of different metabolic marker 18F-fluorodeoxyglucose (18F-FDG) uptake in patients suffering from central nervous system toxicity in relation to the use of Dolutegravir after replacement with Raltegravir. Observe if the anatomic-functional pattern of these patients changes after the substitution of Dolutegravir by Raltegravir. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) Neuropsiquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

31. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial. Full Text available with Trip Pro

STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial. The optimal timing of renal replacement therapy (RRT) initiation in critically ill patients with acute kidney injury (AKI) remains controversial.In critically ill patients with AKI, to determine whether the accelerated initiation of RRT reduces mortality compared to a strategy of standard RRT initiation whereby RRT (...) of ≥27 µmol/L from baseline or urine output <6 mL/kg in preceding 12 hours). Patients will be excluded if 1 or more of the following is/are present: potassium >5.5 mmol/L; bicarbonate <15 mmol/L; concomitant intoxication necessitating RRT; philosophy of care precluding escalation to RRT; any RRT in preceding 2 months; kidney transplant within the past year; preexisting estimated glomerular filtration rate <20 mL/min/1.73 m2; AKI etiology attributable to obstruction, glomerulonephritis, vasculitis

2019 Canadian journal of kidney health and disease Controlled trial quality: predicted high

32. Electronic health records accurately predict renal replacement therapy in acute kidney injury. Full Text available with Trip Pro

Electronic health records accurately predict renal replacement therapy in acute kidney injury. Electronic health records (EHR) detect the onset of acute kidney injury (AKI) in hospitalized patients, and may identify those at highest risk of mortality and renal replacement therapy (RRT), for earlier targeted intervention.Prospective observational study to derive prediction models for hospital mortality and RRT, in inpatients aged ≥18 years with AKI detected by EHR over 1 year in a tertiary (...) till peak), higher serum potassium and baseline eGFR, as independent predictors of both mortality and RRT. Additionally, older age, higher serum urea, pneumonia and intraabdominal infections, acute cardiac diseases, solid organ malignancy, cerebrovascular disease, current need for RRT and admission under a medical specialty predicted mortality. The AUROC for RRT prediction was 0.94, averaging 0.93 after 10-fold cross-validation. Corresponding AUROC for mortality prediction was 0.9 and 0.9 after

2019 BMC Nephrology

33. Can we predict when to start renal replacement therapy in patients with chronic kidney disease using 6 months of clinical data? Full Text available with Trip Pro

Can we predict when to start renal replacement therapy in patients with chronic kidney disease using 6 months of clinical data? We aimed to develop a model of chronic kidney disease (CKD) progression for predicting the probability and time to progression from various CKD stages to renal replacement therapy (RRT), using 6 months of clinical data variables routinely measured at healthcare centers.Data were derived from the electronic medical records of Ajou University Hospital, Suwon, South Korea (...) , respectively. The integral mean was the most powerful explanatory (R2 = 0.404) variable among the 8 modified values. Ten variables (age, sex, diabetes mellitus[DM], polycystic kidney disease[PKD], serum albumin, serum hemoglobin, serum phosphorus, serum potassium, eGFR (calculated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]), and urinary protein) were included in the final risk prediction model for CKD stage 3 (R2 = 0.330). Ten variables (age, sex, DM, GN, PKD, serum hemoglobin, serum

2018 PLoS ONE

34. Long-term potassium intake and associated renal and cardiovascular outcomes in the clinical setting. (Abstract)

Long-term potassium intake and associated renal and cardiovascular outcomes in the clinical setting. High potassium intake has been suggested to lower the risk for renal and cardiovascular outcome, but data are conflicting. This may be explained by the use of different methods for potassium intake assessment across studies. Also, most data are limited to the general population. We investigated the optimal potassium intake, as measured with multiple 24-h urine samples, in patients (...) with a clinical indication for 24-h urine collection, for prevention of cardiorenal disease.We performed a retrospective cohort study in 541 outpatient subjects with an estimated glomerular filtration rate >60 mL/min/1.73 m2 who had sampled a 24-h urine collection between 1998 and 1999, and had at least 1 additional collection during a 17-year follow-up. We assessed incidence of renal (i.e. renal replacement therapy, 60% decline in estimated glomerular filtration rate or death) and cardiovascular disease (i.e

2020 Clinical nutrition (Edinburgh, Scotland)

35. Intellectual Disability and Potassium Channelopathies: A Systematic Review Full Text available with Trip Pro

Intellectual Disability and Potassium Channelopathies: A Systematic Review Frontiers | Intellectual Disability and Potassium Channelopathies: A Systematic Review | Genetics Toggle navigation Section University of Tennessee Health Science Center (UTHSC), United States Reviewed by University of Molise, Italy The University of Utah, United States The editor and reviewers' affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review (...) . TABLE OF CONTENTS total views SHARE ON Systematic Review ARTICLE Front. Genet., 23 June 2020 | Intellectual Disability and Potassium Channelopathies: A Systematic Review 1,2,3,4 † , 1,2 † , 1,2 , Yulin Tang 1,2 , Eleonore Olatoutou 1,2 , Fang He 1,2 , Lifen Yang 1,2 and 1,2 * 1 Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China 2 Hunan Intellectual and Developmental Disabilities Research Center, Changsha, China 3 Kilimanjaro Christian Medical University College

2020 Frontiers in genetics

36. Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial. Full Text available with Trip Pro

Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial. To evaluate the effects of a low-sodium and high-potassium salt-substitute on lowering blood pressure (BP) among Tibetans living at high altitude (4300 meters).The study was a patient-blinded randomized controlled trial conducted between February and May 2009 in Dangxiong County, Tibetan Autonomous Region, China. A total of 282 (...) Tibetans aged 40 or older with known hypertension (systolic BP≥140 mmHg) were recruited and randomized to intervention (salt-substitute, 65% sodium chloride, 25% potassium chloride and 10% magnesium sulfate) or control (100% sodium chloride) in a 1: 1 allocation ratio with three months' supply. Primary outcome was defined as the change in BP levels measured from baseline to followed-up with an automated sphygmomanometer. Per protocol (PP) and intention to treat (ITT) analyses were conducted.After

2014 PloS one Controlled trial quality: uncertain

37. Association between mortality and replacement solution bicarbonate concentration in continuous renal replacement therapy: A propensity-matched cohort study. Full Text available with Trip Pro

Association between mortality and replacement solution bicarbonate concentration in continuous renal replacement therapy: A propensity-matched cohort study. Given the known deleterious effects seen with bicarbonate supplementation for acidemia, we hypothesized that utilizing high bicarbonate concentration replacement solution in continuous venovenous hemofiltration (CVVH) would be independently associated with higher mortality.In a propensity score-matched historical cohort study conducted (...) at a single tertiary care center from December 9, 2006, through December 31, 2009, a total of 287consecutive adult critically ill patients with Stage III acute kidney injury (AKI) requiring CVVH were enrolled. We excluded patients on maintenance dialysis, those who received other modalities of continuous renal replacement therapies, and patients that received a mixed of 22 and 32 mEq/L bicarbonate solution pre- and post-filter. The primary outcome was in-hospital and 90-day mortality rates.Among enrollees

2017 PLoS ONE

38. Pretreatment with glucose-insulin-potassium improves ventricular performances after coronary artery bypass surgery: a randomized controlled trial. Full Text available with Trip Pro

Pretreatment with glucose-insulin-potassium improves ventricular performances after coronary artery bypass surgery: a randomized controlled trial. Heart failure is the main cause of poor outcome following open heart surgery and experimental studies have demonstrated that glucose-insulin-potassium (GIK) infusion exerts cardioprotective effects by reducing myocardial ischemia-reperfusion injuries. This randomized controlled trial was designed to assess the effects of GIK on left ventricular (...) function in moderate-to-high risk patients undergoing on-pump isolated coronary artery bypass surgery (CABGS), or combined with aortic valve replacement. The primary outcomes were the effects of GIK on two- and three-dimensional left ventricular ejection fraction (2D and 3D-LVEF), and on transmitral flow propagation velocity (Vp), that occurred between the pre- and post-CPB periods. GIK administration was associated with favorable interaction effects (p < 0.001) on 2D-LVEF, 3D-LVEF and Vp changes over

2019 Journal of clinical monitoring and computing Controlled trial quality: predicted high

39. Can potassium be given by subcutaneous infusion?

Can potassium be given by subcutaneous infusion? Can potassium be given by subcutaneous infusion? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · Published 13th June 2016, updated 7th November 2018 This Medicines Q&A considers whether potassium can be administered subcutaneously to patients receiving fluid replacement by hypodermoclysis Attachments · Word · 67 KB Principal Pharmacist Critical Evaluation and UKMi Medicines Q&A Lead, Southampton

2016 Specialist Pharmacy Services

40. Efficacy and safety of a phosphate replacement strategy for severe hypophosphatemia in the ICU. (Abstract)

hypophosphatemia (p = 0.01). Mild hyperphosphatemia was observed in one patient only (1.53 mmol/l), hyperkalemia was observed in three patients (all three had severe hypophosphatemia, average potassium after supplementation was 5.2 ±; 0.2 mmol/l) and serum calcium levels remained unchanged in both groups.Individualized phosphate replacement was effective and safe for both moderate and severe hypophosphatemia, but was more accurate in moderate hypophosphatemia. (...) Efficacy and safety of a phosphate replacement strategy for severe hypophosphatemia in the ICU. Experience with individualized phosphate replacement is limited in patients with severe hypophosphatemia. This study compares the efficacy and safety of an individualized regimen of serum phosphate < 0.4 mmol/l treatment in ICU patients to patients with moderate hypophosphatemia (0.4-0.6 mmol/l).This retrospective cohort study included 36 patients with severe and 35 patients with moderate

2018 Netherlands Journal of Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>